The comparison of effect between salsalate and placebo in osteoarthritis patients with nonalcoholic fatty liver disease

Not Applicable

Recruiting

• Conditions: Diseases of the musculo-skeletal system and connective tissue

• Registration Number: KCT0002441
• Lead Sponsor: Koera University Guro Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 11 March 2019

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 34

Inclusion Criteria

1. Over 19 years old
2. Osteoarthritis patients with nonalcoholic fatty liver
3. Diagnostic criteria for nonalcoholic fatty liver (all satisfied)
- Abdominal ultrasound image Fatty liver
- Patients without evidence of other chronic hepatitis such as hepatitis B, hepatitis C, immune hepatitis, metabolic hepatitis
- Less than 210 g drinking per week in men, less than 140 g drinking per week in women
4. Osteoarthritis not receiving treatment

Exclusion Criteria

1. Persons who do not meet the Inclusion criteria
2. Thiazolidinedione is administered for the treatment of diabetes, or drug has been changed within the past 6 months
3. Patients undergoing treatment such as nonsteroidal anti-inflammation for osteoarthritis
4. Patients with renal impairment
Serum creatinine level 1.5 mg / dL or creatinine clearance <60 mL / min
5. Patients with a history of gastrointestinal bleeding
6. Patients whose AST and ALT exceed 5 times the normal upper limit (200 IU / L)
8. Pregnant or lactating women
9. Other untreated malignant tumors
10. Patients who received liver transplant
11. Liver function Child-Pugh B or more patients
12. In case of serious diseases judged to be able to affect the study (eg, congestive heart failure, renal failure, chronic pancreatitis, malignant tumor etc.)
13. Patients with a history of having been administered the current immunomodulatory agent / immunosuppressant (including systemic corticosteroids administration) within 6 months prior to study registration
14. Subjects judged to be nonconformities by other researchers
: It must not be under any of the above exclusion criteria.

Study & Design

• Study Type: Interventional Study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The change of hepatokines;The change of adipokines

Secondary Outcome Measures

Name	Time	Method
The change of hepatokines;The change of adipokines;The change of fatty liver and fibrosis index;The change of metabolic index;The change of liver function test and lipid profile;The change of inflammation mediators;The change of liver fibrosis factor;The change of symptoms and function of osteoarthritis;Safety (Side effect)